Through
4/26
Penn researchers have shown success using genetically engineered macrophages, an immune cell that eats invaders in the body, to target solid tumors.
Researchers within the Penn Pancreatic Research Center and beyond continue to seek innovative ways to treat and detect this deadly disease—and are making promising progress.
A Penn study shows a better clinical response to immunotherapy correlates with higher ratio of tumor mutations detected by a liquid biopsy.
How do you talk about cancer risk? How do you make major life decisions knowing you are likely to develop cancer? Allison Werner-Lin looks at these questions, studying the intersection of genetics and family life.
In the first U.S. clinical trial, cells removed from patients and brought back into the lab were able to kill cancer months after their original manufacturing and infusion.
A new study identifies the mechanism that prevents cell death, and can guide future immunotherapy strategies in patients whose blood cancers are resistant to CAR T therapy.
By using messenger RNA across the T cell’s membrane via a nanoparticle instead of a DNA-rewriting virus on extracted T cells, CAR T treatments could have fewer side effects.
Glioblastoma organoids grown from patients’ own glioblastoma tissue can be used to investigate personalized treatment approaches in time-sensitive cases.
Findings related to FLASH radiotherapy—using protons rather than electrons—prove feasible in the future for cancer therapy.
Proton therapy leads to a significantly lower risk of side effects severe enough to lead to unplanned hospitalizations for cancer patients when compared with traditional radiation. Cure rates between the two groups are almost identical.
A 2020 study from the Perelman School of Medicine found that a blood test to screen for certain biomarkers associated with pancreatic cancer was 92% accurate in its ability to detect disease.
FULL STORY →
A clinical trial led by Stephen Bagley of the Perelman School of Medicine suggests that targeting two associated proteins with CAR T cell therapy could be a viable strategy for shrinking brain tumors.
FULL STORY →
Penn Medicine researchers like Nobel laureate Drew Weissman are leading efforts to develop a vaccine that prevents cancer, with remarks from Susan Domchek of the Basser Center for BRCA and Robert H. Vonderheide of the Abramson Cancer Center.
FULL STORY →
A trial led by Susan Domchek of the Perelman School of Medicine could use a preventive vaccine to protect people with a BRCA gene mutation from cancer.
FULL STORY →
Daiwei Zhang and Mingyao Li of the Perelman School of Medicine and colleagues have developed an AI tool called iStar that can automatically spot tumors and types of cancer that are difficult for clinicians to see or identify and can predict candidates for immunotherapy.
FULL STORY →
The Abramson Cancer Center is attempting to address one of the most common challenges cancer patients face: lack of transportation to critically important appointments. Robert Vonderheide and Carmen Guerra of the Perelman School of Medicine are quoted on the Ride Health initiative.
FULL STORY →